ArsenalBio lands $70M cash deal with cancer giant Genentech to develop cell therapy
San Francisco-based ArsenalBio’s designer T cells program is attracting the attention of some big players.
After closing a deal and grabbing $70 million in cash from Bristol Myers Squibb last year, the company is back in the news with a brand new deal, this time with Genentech.
ArsenalBio will receive $70 million upfront from Genentech along with research support, the companies announced Tuesday. Under the collaboration, both companies will share research ideas and develop targeted T cells for solid tumors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.